Ballentine Partners, LLC Argenx Se Transaction History
Ballentine Partners, LLC
- $5.81 Billion
- Q4 2024
A detailed history of Ballentine Partners, LLC transactions in Argenx Se stock. As of the latest transaction made, Ballentine Partners, LLC holds 536 shares of ARGX stock, worth $351,149. This represents 0.01% of its overall portfolio holdings.
Number of Shares
536
Previous 441
21.54%
Holding current value
$351,149
Previous $239,000
37.66%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ARGX
# of Institutions
413Shares Held
31MCall Options Held
376KPut Options Held
489K-
Price T Rowe Associates Inc Baltimore, MD5.82MShares$3.81 Billion0.36% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$2.3 Billion2.99% of portfolio
-
Janus Henderson Group PLC London, X02.48MShares$1.62 Billion0.72% of portfolio
-
Capital World Investors Los Angeles, CA1.7MShares$1.11 Billion0.15% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$811 Million10.11% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $36.2B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...